Skip to main content

Roser Ferrer Costa

I'm the Head of Clinical Biochemistry Service at Hospital's Clinical Laboratories and co-chief of Clinical Biochemistry Group, Pharmaceutical Vehiculation and VHIR Research Therapy. I lead a team of professionals in clinical biochemistry, developing care, teaching and research, with a project towards the highest excellence. I am a PhD in Biomedicine for UB, a specialist in the area of knowledge of clinical biochemistry of hormones and a master's degree in Health Institutions Management and currently an Associate Professor of the UAB.

Institutions of which they are part

Head of group
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca
Head of Department
Bioquímica
Cross-departmental services

Roser Ferrer Costa

Institutions of which they are part

Head of group
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca
Head of Department
Bioquímica
Cross-departmental services

I'm the Head of Clinical Biochemistry Service at Hospital's Clinical Laboratories and co-chief of Clinical Biochemistry Group, Pharmaceutical Vehiculation and VHIR Research Therapy. I lead a team of professionals in clinical biochemistry, developing care, teaching and research, with a project towards the highest excellence. I am a PhD in Biomedicine for UB, a specialist in the area of knowledge of clinical biochemistry of hormones and a master's degree in Health Institutions Management and currently an Associate Professor of the UAB.

Healthcare activity:
Since 2007 I have been working at the University Hospital, where I trained as a specialist in Clinical Biochemistry (2003). I am a trained pharmacist and until 2019 I was responsible for the Hormone Process (Endocrin Pathology) of the same Service and later Head of Section of the Automated Laboratory. Since 2023, I have been Head of Clinical Biochemistry Service.

The Clinical Biochemistry Service is part of the Clinical Laboratories of the Vall d'Hebron University Hospital, which also provides coverage for the entire population, with pubic health care, of the city of Barcelona (1.5 million people).
In 2019 I completed my master's degree in Health Institutions Management, I have training in healthcare processes and specialisation in automation, concepts that I try to apply in my usual practice and in the Service. Finally, I am the secretary of the hospital's In Vitro Diagnostic Commission.

Research activity:
I am a Doctor of Biomedicine from the University of Barcelona (2015) and co-chief of Clinical Biochemistry Group, Vehiculation of Pharmacists and Therapy Research from the Research Institute of the Vall d'Hebron University Hospital since 2023. In recent years I have been actively involved in different publications of the Service itself and in collaboration with research groups and hospital services.
Attached to the eCore Personalized Medicine, Innovative Diagnostics, Molecular Imaging . Digital Health of VHIR.
I am president of the Catalan Clinical Laboratory Science Association (since June 2021) and member of the Hormone Commission (since 2011) and of the Executive Committee (since 2018) of the Spanish Society of Medicine of the Laboratory (SEQCML).

Docent Activity:
I am currently Associate Professor of the Autonomous University of the Department of Biochemistry and Molecular Biology, Medicine Biochemistry Unit.
I am participating in the postgraduate doctoral thesis management of the Biochemistry Service.

Research lines

Determinación de hormonas con alta sensibilidad

IP: Roser Ferrer Costa, Marina Giralt Arnaiz

Laboratory management and automatitzation

IP: Ernesto Casis Saenz, Roser Ferrer Costa, Clara Ramírez Serra

Anàlisi de dades massives (big data), explotació de dades i mostres als Laboratoris Clínics

IP: Roser Ferrer Costa

Projects

TACTIC: Explorando soluciones a los retos de salud mediante ciencia disruptiva, terapias avanzadas y medicina de sistemas

IP: Begoña Benito Villabriga
Collaborators: Carmen Escudero Iriarte, Laia Ventura i Expósito, Susana Otero Romero, TACTIC: Explorando soluciones a los retos de salud mediante ciencia disruptiva, terapias avanzadas y medicina de sistemas, Ignacio Ferreira González, José Antonio Barrabés Riu, Carlos Nos Llopis, Pablo Velasco Puyó, Jose Fernando Rodríguez Palomares, María Rosario Pérez- Torres Lobato, Sunny Malhotra Sareen, Perez Dueñas, Belen, Jaume Sastre Garriga, Joan López Hellin, Antonia Sambola Ayala, Jordi Rio Izquierdo, Nuria Rivas Gandara, Jordi Perez Rodon, Aroa Soriano Fernández, Manuel Comabella Lopez, Antonio Rodríguez Sinovas, Gisela Teixido Tura, Antonia Pijuan Domenech, Roser Ferrer Costa, Joaquin Seras Franzoso, Carmen Tur Gomez, Maria Cristina Díaz de Heredia Rubio, Laia Yañez Bisbe, Julia German Cortes, Maria Jose Pérez García, Miguel Segura Ginard, Diego Baranda Martínez-Abasca, Cristina Auger Acosta, Neus Bellera Gotarda, Herena Eixarch Ahufinger, M Mar Mañu Pereira, Deborah Pareto Onghena, Lorena Valero Arrese, Aitor Uribarri Gonzalez, Jordi Bañeras Rius, Alex Rovira Cañellas, Mar Tintore Subirana, Bruno García del Blanco, Maria Teresa Salcedo Allende, Marisol Ruiz Meana, Ana Belén Méndez Fernández, Xavier Montalban Gairín, Simon Schwartz Navarro, Anna Llort Sales, Carmen Espejo Ruiz, Raquel Hladun Alvaro, Angels Alcina Mila, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Ana Zabalza de Torres, Ariadna Boloix Amenós, Marc Miquel Moltó Abad, Javier Inserte Igual, Luciana Midaglia Fernandez, Elizabeth Pando Rau, Gabriela Guillén Burrieza, Cazurro Gutierrez, Ana Laura, Gómez Andrés, David, Alvaro Cobo Calvo, Alvaro Calabuig Goena, Joaquin Castillo Justribo, Lydia Dux-Santoy Hurtado, Lucas Moreno Martín-Retortillo, Andres Miguez Gonzalez, Josep Roma Castanyer, Laura Dos Subirá, Nicolás Miguel Fissolo, Maria Nazarena Pizzi, Tian Tian, Bou Teen, Diana, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Andrea Guala
Funding agency: Instituto de Salud Carlos III
Funding: 2494527.53
Reference: FORT23/00034
Duration: 01/01/2024 - 31/12/2027

(HEPAST) - Estrategias de terapia genica para controlar la infeccion por los virus de la Hepatitis B y Delta basada en el estudio de las cuasiespecies virales por secuenciación masiva

IP: Francisco Rodríguez Frias
Collaborators: Roser Ferrer Costa
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 157300
Reference: PID2021-126447OB-I00
Duration: 01/09/2022 - 01/09/2025

Ministerio de Ciencia

Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT)

IP: Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT)
Collaborators: José Antonio Arranz Amo, Raquel Barquin Del Pino, Laura Conesa Milian, Clara Ramírez Serra, Yolanda Villena Ortiz, Joan López Hellin, Albert Blanco Grau, Francisco Rodríguez Frias, Roser Ferrer Costa, Joaquin Seras Franzoso, Diego Baranda Martínez-Abasca, Laura Castillo Ribelles, Clara Carnicer Cáceres, Marina Giralt Arnaiz, Ana Gomez Garcia, Simon Schwartz Navarro, Pablo Gabriel Medina, Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT), Zamira Vanessa Diaz Riascos, Marc Miquel Moltó Abad, Laura Castellote Bellés, Daniel Bravo Nieto, Luz María Cruz Carlos, Clara Sanz Gea, Alba Estela García Fernández, Maria del Pilar Reimundo Diaz-Fierros, Belen Garcia Prats, Noelia Díaz Troyano, JAUME VIMA BOFARULL, Beatriz Pacín Ruíz, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Maria Francesca Cortese, Sandra Mancilla Zamora
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 60000
Reference: 2021 SGR 01173
Duration: 01/01/2022 - 30/06/2025

COVID-19, PERFIL INMUNOLÓGICO DE RIESGO

IP: COVID-19, PERFIL INMUNOLÓGICO DE RIESGO
Collaborators: Manuel Hernández González, Mónica Martínez Gallo, Moisés Labrador Horrillo, Gema Codina Grau, Albert Blanco Grau, Andres Antón Pagarolas, Antonio Álvarez Fernandez, Nuria Fernández Hidalgo, Roser Ferrer Costa, Esteve Ribera Pascuet, Juan Carlos Ruiz Rodriguez, Jaume Ferrer Sancho, Anna Suy Franch, Pere Soler Palacín, Albert Selva O'Callaghan, Tomàs Pumarola Suñé, Isabel Ruiz Camps, Daniel Alvarez De la Sierra, Andrea Martín Nalda, Eva Polverino, Romina Dieli Crimi, Romina Dieli Crimi
Funding agency: Instituto de Salud Carlos III
Funding: 229000
Reference: COV20/00416
Duration: 08/05/2020 - 08/11/2021

Related news

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.

During the last year, the collaboration between Vall d’Hebron and ZeClinics has found three nanobody candidates with potent anticancer properties in zebrafish model.

Related professionals

Marc Simo Perdigo

Marc Simo Perdigo

Molecular Medical Imaging
Read more
Joaquim Sola  Santesmases

Joaquim Sola Santesmases

Zelador/a
General Services and Infrastructures Unit
Manager
Read more
Javier Domeño Baztán

Javier Domeño Baztán

Research technician
Clinical Neuroimmunology
Read more
Thais Cuadros Arasa

Thais Cuadros Arasa

Postdoctoral researcher
Neurodegenerative Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.